ATAI Life Sciences B.V.* ATAI 深 沪
已收盘 09-12 16:00:00 美东时间
4.63
+0.030
+0.65%
华盛通- 最 高4.75
- 今 开4.60
- 成交量 335.69万股
- 最 低 4.56
- 昨 收 4.60
- 总市值 9.82亿
- 52周最高 5.34
- 市盈率 静 --
- 换手率 1.58%
- 52周最低 1.03
- 委 比 12.01%
- 总股本 2.12亿
- 历史最高 22.91
- 量 比 0.91
- 振 幅 4.13%
- 历史最低 1.025
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多'Massachusetts Lawmakers Approve Bill To Create Psychedelic Therapy Pilot Program' - Marijuana Moment
https://www.marijuanamoment.net/massachusetts-lawmakers-approve-bill-to-create-psychedelic-therapy-pilot-program/
09-13 00:30
'U.S. Senate Committee To Hold Hearing On Benefits Of Psychedelics For Military Veterans'- Marijuana Moment
https://www.marijuanamoment.net/u-s-senate-committee-to-hold-hearing-on-benefits-of-psychedelics-for-military-veterans/
08-22 02:35
ATAI Life Sciences Q2 EPS $(0.14) Misses $(0.12) Estimate, Sales $719.000K Up From $273.000K YoY
ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 61.11 percent increase over losses of $(0.36) per share
08-14 19:17
Which under-the-radar winners have the best chance for further gains?
Looking for smaller stocks that have attracted strong investor interest so far in 2025, but are still positioned for further gains? The list below is meant to focus on those names. It contains stocks ...
08-07 22:15
精神健康成医药并购新风口！传艾伯维(ABBV.US)正洽谈收购Gilgamesh 估值或达10亿美元
据知情人士透露，艾伯维正在洽谈收购专注于精神健康治疗的Gilgamesh Pharmaceuticals。如果交易成功，将增强艾伯维在精神疾病治疗方面的产品管线。
07-31 08:52
美股大行评级 | 微软获上调目标价最高至570美元；摩根大通维持网易"超配"评级，目标价升至140美元
今日重点评级关注：Leerink Partners：维持Celcuity"跑赢大市"评级，目标价从28美元升至60美元；Macquarie：维持Churchill Downs"跑赢大市"评级，目标价从150美元升至155美元
07-29 09:30
Market-Moving News for July 28th
CELC: 133% | Celcuity Released Topline Results From PIK3CA Wild-Type Cohort Of Phase 3 VIKTORIA-1 Trial Of Gedatolisib Plus Fulvestrant With And Without Palbociclib Versus Fulvestrant In Advanced Breast
07-28 19:36
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
<p>A Phase 2b clinical trial evaluating inidascamine for cognitive impairment associated with schizophrenia did not meet its primary endpoint, though showed numerical improvements in cognitive and functional measures. The drug exhibited a favorable safety profile with no evidence of sedation, weight gain, or extrapyramidal symptoms. Full data analysis, including secondary endpoints and subgroup analyses, is ongoing to explore potential responder ...
07-25 20:05
'California Governor He's 'All In' On Psychedelic Therapy Access, But Worries About Capitalists Commercializing It' - Marijuana Moment
https://www.marijuanamoment.net/california-governor-hes-all-in-on-psychedelic-therapy-access-but-worries-about-capitalists-commercializing-it/
07-21 22:21
美股大行评级 | 潜在涨幅336.36%！Canaccord Genuity上调ATAI Life Sciences目标价至12美元，维持"买入"评级
Redburn Atlantic：下调Adobe(ADBE)评级至"卖出"，目标价从420美元降至280美元
07-03 11:01
